title: Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis.
abstract: BACKGROUND
  Several cases of obesity-associated focal segmental glomerulosclerosis (OB-FSG) have been reported but little is known about the clinico-pathological features of this entity and its long-term outcomes.
  
  
  METHODS
  We studied 15 obese patients (BMI 35+/-5.2 kg/m(2)) with biopsy-proven FSG. They were compared with a control group of 15 non-obese patients with idiopathic FSG (I-FSG).
  
  
  RESULTS
  Mean proteinuria at the time of renal biopsy was 3.1+/-2 g/24 h in OB-FSG; it reached the nephrotic range (> or =3.5 g/24 h) during follow-up in 12 patients (80%), but none of them had oedema, hypoproteinaemia, or hypoalbuminaemia. Proteinuria was more marked amongst I-FSG (6.5+/-4.2 g/24 h) and most of them developed oedema and biochemical nephrotic syndrome. Glomerulomegaly was observed in all renal biopsies from OB-FSG patients (mean glomerular diameter 256+/-24 microm in OB-FSG vs 199+/-26 microm in I-FSG, P<0.001). Twelve OB-FSG patients (80%) were treated with ACE inhibitors (ACEI) and proteinuria significantly decreased within the first 6 months of treatment but showed a later increase. None of the obese patients achieved a sustained weight loss. Seven (46%) patients with OB-FSG experienced a progressive renal insufficiency and five of them started intermittent dialysis. Kaplan-Meier estimated probabilities of renal survival after 5 and 10 years were 77 and 51%, respectively, in OB-FSG patients, and 52 and 30% in I-FSG (P<0.05). The risk of developing progressive renal failure among OB-FSG patients was statistically correlated with serum creatinine and creatinine clearance at presentation.
  
  
  CONCLUSIONS
  OB-FSG indicates a poor prognosis with almost one-half of patients developing advanced renal failure. Knowledge of the clinico-pathological features of this entity (obesity, FSG lesions with glomerulomegaly, absence of nephrotic syndrome despite nephrotic-range proteinuria) should be helpful in establishing an accurate and early diagnosis.
authors.affiliation: Department of Nephrology, Hospital Universitario 12 de Octubre, Carretera de Andalucia, Km 5, 400, E-28041 Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Praga
authors.forename: E
authors.initials: E
authors.lastname: Hernández
authors.forename: E
authors.initials: E
authors.lastname: Morales
authors.forename: A P
authors.initials: AP
authors.lastname: Campos
authors.forename: M A
authors.initials: MA
authors.lastname: Valero
authors.forename: M A
authors.initials: MA
authors.lastname: Martínez
authors.forename: M
authors.initials: M
authors.lastname: León
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology / Q000652:urine; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D011379:Prognosis; D011507:Proteinuria / Q000209:etiology; D051437:Renal Insufficiency / Q000209:etiology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D003404:Creatinine